Stocktwits on MSN

REPL, HOTH, ONCO stocks hit 52-week lows: What's driving the selloff in these biotech plays?

REPL came under pressure after the FDA issued a second Complete Response Letter for RP1 with nivolumab in anti-PD-1-failed melanoma. ・HOTH declined after a $2 million stock offering, along with ...

Street sours on Replimune as stock hits all-time low on melanoma drug rejection

As shares of Replimune Group ( REPL) hit an all-time low on Monday of $1.50 following the US FDA's rejection of its lead ...

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

REPL stock plunges after a second FDA CRL delays RP1 melanoma approval, casting doubt on its regulatory path and near-term growth plans.

Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives

Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...
Stocktwits on MSN

REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays

Analysts estimate about 116% upside for REPL, compared to a 124% upside for IOVA from current levels. ・Amtagvi, already approved for melanoma, helped Iovance generate about $264 million in product ...

Replimune melanoma therapy rejected by FDA, shares plunge

Replimune Group (NASDAQ:REPL) shares fell roughly 63% following the company’s disclosure that it received a Complete Response ...